Two Sigma Advisers’s Biogen BIIB Stock Holding History

Two Sigma Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-10,000	Closed	-$3.31M	–	2435
2014 Q3	$3.31M	Sell	10,000 -24,000	-71%	-$7.91M	0.02%	630
2014 Q2	$10.7M	Buy	34,000 +29,000	+580%	+$8.73M	0.08%	270
2014 Q1	$1.53M	Sell	5,000 -1,000	-17%	-$317K	0.01%	898
2013 Q4	$1.68M	Sell	6,000 -3,000	-33%	-$776K	0.02%	837
2013 Q3	$2.17M	Buy	9,000 +8,000	+800%	+$1.79M	0.03%	599
2013 Q2	$215K	Buy	+1,000	New	+$214K	﹤0.01%	1930

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Two Sigma Advisers's BIIB Position: Q1 2026 in Review

Two Sigma Advisers sold out of Biogen (BIIB) in Q1 2026, closing a stake of 8,800 shares — an estimated $1.55M sold.

Two Sigma Advisers first reported a position in BIIB in Q2 2013 and held it in 41 quarters. The position peaked at $234M in Q3 2022. 1,011 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Two Sigma Advisers reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 8,800 Biogen shares in Q1 2026, an estimated $1.55M.
Two Sigma Advisers first reported a position in Biogen in Q2 2013 and held it in 41 quarters.
Two Sigma Advisers's Biogen position peaked at $234M in Q3 2022.
1,011 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.